Clinical trials with bis-dioxopiperazine propane (ICRF 159; NSC 129, 943) in acute leukaemias.
Clinical experience is reported with bis-dioxopiperazine propane (ICRF 159) in 20 children with acute leukaemia in relapse. They were resistant to most of the generally used cytotoxic drugs. Despite the unfavourable selection of cases, two complete and seven incomplete remissions lasting from 1 to 6 months were obtained.